Fig. 2.
Fig. 2. EGFP and murine CD40L expression after rAAV transduction (MOI 100). / Primary B-CLL cells derived from patients 4, 5, 21, and 22 (Table 1) were transduced at an MOI of 100 with rAAV vectors encoding EGFP (A) and CD40L (B) and analyzed for transgene by flow cytometry 48 hours later. The graphs on the left of each panel (control) represent the autofluorescence (EGFP) and isotype (CD40L) controls, respectively, and the graphs on the right of each panel show the cells transduced with rAAV vectors (AAV/EGFP, AAV/CD40L). Dot-plot analysis of the double staining for the B-cell lineage marker CD19 (Cy5-conjugated mAb; y-axis) and transgene expression (EGFP and PE-conjugated anti–murine CD40L; x-axis) is shown.

EGFP and murine CD40L expression after rAAV transduction (MOI 100).

Primary B-CLL cells derived from patients 4, 5, 21, and 22 (Table 1) were transduced at an MOI of 100 with rAAV vectors encoding EGFP (A) and CD40L (B) and analyzed for transgene by flow cytometry 48 hours later. The graphs on the left of each panel (control) represent the autofluorescence (EGFP) and isotype (CD40L) controls, respectively, and the graphs on the right of each panel show the cells transduced with rAAV vectors (AAV/EGFP, AAV/CD40L). Dot-plot analysis of the double staining for the B-cell lineage marker CD19 (Cy5-conjugated mAb; y-axis) and transgene expression (EGFP and PE-conjugated anti–murine CD40L; x-axis) is shown.

Close Modal

or Create an Account

Close Modal
Close Modal